The global Eosinophilic Esophagitis Market is estimated to be valued at US$ 245.92 Mn in 2023 and is expected to exhibit a CAGR of 33% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Eosinophilic Esophagitis is a chronic immune/antigen-mediated disease characterized by eosinophil-predominant inflammation localized to the esophagus. Symptoms include dysphagia, food impaction, gastroesophageal reflux, abdominal pain and vomiting. Diagnosis involves endoscopy with biopsy. Treatment includes dietary therapy, drugs like corticosteroids and biological therapy.

Market key trends:
The key trend in Eosinophilic Esophagitis Market is increasing adoption of targeted biologics especially in severe refractory cases. Budesonide, a steroid, is the current standard of care. However, newer biologics like Dupilumab, which targets type 2 cytokine pathways involved in eosinophilic inflammation, have shown promising results in clinical trials. Therapies targeting IL-5 and its receptor pathways, that are major drivers of eosinophil activation and survival, are also in preclinical studies. This increased focus on targeted immunomodulatory biologics is helping address unmet needs of patients with severe refractory disease.

SWOT Analysis
Strength: Eosinophilic Esophagitis market is witnessing high growth due to rising prevalence of food allergies and environmental allergies. Increasing research and development activities by key players for development of novel treatment options is also driving the market growth.
Weakness: Lack of awareness regarding Eosinophilic Esophagitis in developing regions hampers the market growth. High cost of treatment and diagnosis techniques are also major challenges for market players.
Opportunity: Increasing healthcare spending in developing regions create lucrative opportunities for market players. Growing geriatric population susceptible to food allergies will augment the product demand in upcoming years.
Threats: Stringent regulatory framework for drugs approval and clinical trials may increase the development cost for market players. Patent expiries of major drugs can negatively impact the market revenues.

Key Takeaways
The Global Eosinophilic Esophagitis Market Share is expected to witness high growth, exhibiting CAGR of 33% over the forecast period, due to increasing prevalence of food allergies across developed nations.

Regional analysis: North America captured over 45% share of global Eosinophilic Esophagitis market in 2023 owing to rising disease diagnosis and availability of advanced treatment facilities in the US and Canada. Asia Pacific is anticipated to emerge as the fastest growing regional market till 2030 with double digit CAGR backed by improving healthcare infrastructure and increasing healthcare spending in China and India.

Key players: Key players operating in the Eosinophilic Esophagitis market are Ellodi Pharmaceuticals, EsoCap AG, GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., Cipla Limited, Sun Pharmaceutical Industries Limited, AstraZeneca Plc, Sanofi S.A., Arena Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Revolo Biotherapeutics, Allakos Inc., Bristol-Myers Squibb Co, Calypso Biotech, DBV Technologies, Landos Biopharma, Inc., Glenmark Pharmaceuticals, Alkem Laboratories Ltd., Quorum Innovations LLC, and Dr. Falk Pharma GmbH. Major players are focused on developing advanced treatment for long term disease management.

For more insights, Read-

https://perfectinsights.blogspot.com/2023/12/the-rising-application-of-biologics-and.html